Skylands Capital LLC Trims Position in biote Corp. (NASDAQ:BTMD)

Skylands Capital LLC decreased its holdings in biote Corp. (NASDAQ:BTMD) by 19.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 159,500 shares of the company’s stock after selling 39,000 shares during the quarter. Skylands Capital LLC owned about 0.29% of biote worth $986,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of biote during the fourth quarter valued at about $76,000. Thompson Davis & CO. Inc. purchased a new position in shares of biote during the 4th quarter worth approximately $77,000. MetLife Investment Management LLC raised its position in shares of biote by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after acquiring an additional 9,343 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of biote by 24.7% in the 3rd quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock valued at $94,000 after purchasing an additional 3,342 shares during the period. Finally, Quarry LP bought a new stake in shares of biote during the third quarter valued at approximately $104,000. Institutional investors own 21.68% of the company’s stock.

Analyst Ratings Changes

Separately, Craig Hallum began coverage on biote in a research report on Monday, December 16th. They set a “buy” rating and a $12.00 price objective for the company.

biote Stock Performance

Shares of BTMD opened at $4.49 on Monday. The firm’s 50-day simple moving average is $5.54 and its two-hundred day simple moving average is $5.73. biote Corp. has a fifty-two week low of $4.45 and a fifty-two week high of $8.44. The stock has a market cap of $243.97 million, a PE ratio of 17.27 and a beta of 1.04.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.